Amarin reported $143.56M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amarin USD 143.56M 12.5M Jun/2026
AstraZeneca USD 4.89B 2.67B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
DBV Technologies USD 174.9M 54.3M Jun/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Halozyme Therapeutics USD 163.14M 146.61M Jun/2026
Heron Therapeutics USD 20.72M 5.4M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novartis USD 7.62B 739M Jun/2026